Search Result

Results for "

MK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MAPKAPK2 (MK2) (13) Apoptosis (1) Autophagy (5) ERK (2) HSP (4) JNK (2) p38 MAPK (10)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Inflammation/Immunology (14) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Targets Recommended: MAPKAPK2 (MK2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10072A

MK2-IN-5 acetate Hsp25 kinase inhibitor acetate; MK2 pseudosubstrate acetate	JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK	Others
MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation ^[2] .

HY-12834A

MK2-IN-1 hydrochloride 3 Publications Verification	MAPKAPK2 (MK2) HSP	Cancer
MK2-IN-1 hydrochloride (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 0.11 uM for MK2 and an EC₅₀ of 0.35 uM for pHSP27. MK2-IN-1 hydrochloride impaires the phosphorylation level of serine residues in the Tfcp2l1 protein ^[2].

HY-P10072

MK2-IN-5 Hsp25 kinase inhibitor; MK2 pseudosubstrate	ERK JNK p38 MAPK HSP MAPKAPK2 (MK2)	Others
MK2-IN-5 is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation ^[2] .

HY-147283

MK2-IN-4	MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor with an IC₅₀ value of 45 nM. MK2-IN-4 can be used in the research of cancer, inflammation, immunology .

HY-12834

MK2-IN-1	MAPKAPK2 (MK2) HSP	Cancer
MK2-IN-1 (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 0.11 uM for MK2 and an EC₅₀ of 0.35 uM for pHSP27. MK2-IN-1 impaires the phosphorylation level of serine residues in the Tfcp2l1 protein ^[2].

HY-131249

MK2-IN-3 2 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 is a potent and selective inhibitor of **MAPKAP-K2 (MK-2), with an IC₅₀** of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC₅₀s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC₅₀s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .

HY-112457

MK2-IN-3 hydrate 2 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive **MAPKAP-K2 (MK-2) inhibitor with an IC₅₀** of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC₅₀=0.21 μM), MK-5 (IC₅₀=0.081 μM), ERK2 (IC₅₀=3.44 μM), MNK1(IC₅₀=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .

HY-W726640

Peraquinsin	MAPKAPK2 (MK2)	Cardiovascular Disease Metabolic Disease
Peraquinsin is a MK2 activator. Peraquinsin can be used for the research of vascular disorder or endothelial barrier disorder. Peraquinsin also is an antihypertensive agent .

HY-108643

CMPD1

MAPKAPK2 (MK2) Cancer

CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent K_i (K_i ^app) of 330 nM ^[2].

CMPD1	MAPKAPK2 (MK2)	Cancer
CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent K_i (K_i ^app) of 330 nM ^[2].

HY-P3412

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

HY-139553

Zunsemetinib ATI-450; CDD-450	MAPKAPK2 (MK2)	Inflammation/Immunology
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-120111

MW-150 MW01-18-150SRM	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-139553A

(R)-Zunsemetinib (R)-ATI-450; (R)-CDD-450	Others	Inflammation/Immunology
(R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-139504

Gamcemetinib CC-99677	MAPKAPK2 (MK2)	Inflammation/Immunology
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC₅₀=156.3 nM) and cell based assays (EC₅₀=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .

HY-120111A

MW-150 hydrochloride MW01-18-150SRM hydrochloride	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-151921

Anti-inflammatory agent 33	p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 33 is a potent p38α inhibitor. Anti-inflammatory agent 33 inhibits NO production. Anti-inflammatory agent 33 inhibits LPS-induced iNOS, COX-2, p-p38α, p-MK2 protein expression. Anti-inflammatory agent 33 shows anti-inflammatory activity .

HY-13241

Ralimetinib dimesylate Maximum Cited Publications 12 Publications Verification LY2228820 dimesylate	p38 MAPK Autophagy Apoptosis	Inflammation/Immunology Cancer
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-107427

PF-3644022	MAPKAPK2 (MK2) p38 MAPK	Inflammation/Immunology
PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 5.2 nM and a K_i of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC₅₀s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect .

HY-120111B

MW-150 dihydrochloride dihydrate MW01-18-150SRM dihydrochloride dihydrate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-13241A

Ralimetinib LY2228820	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc .

HY-150612

(R)-STU104	p38 MAPK	Cancer
(R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC₅₀s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis .

MK2-IN-5 acetate Hsp25 kinase inhibitor acetate; MK2 pseudosubstrate acetate	JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK	Others
MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation ^[2] .

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

MK2-IN-5 Hsp25 kinase inhibitor; MK2 pseudosubstrate	ERK JNK p38 MAPK HSP MAPKAPK2 (MK2)	Others
MK2-IN-5 is a *Mk2* pseudosubstrate (K_i= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation ^[2] .

Species:	Human (3)
Tag:	His (1) Tag Free (2)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P702662

	MAPKAPK2 Protein, Human (323a.a) MAPKAPK2; mitogen-activated protein kinase-activated protein kinase 2; MAP kinase-activated protein kinase 2; MAPKAP kinase 2; MAPK-activated protein kinase 2; MK2; MK-2; MAPKAP-K2	Human	E. coli

HY-P701805

	MAPKAPK2 Protein, Human (His) MAPKAPK2; MAP kinase-activated protein kinase 2; MAPK-activated protein kinase 2; MAPKAP kinase 2; MAPKAP-K2; MAPKAPK-2; MK-2; MK2	Human	E. coli
	The MAPKAPK2 protein is a stress-activated kinase involved in multiple cellular processes, including cytokine production, endocytosis, cytoskeletal reorganization, cell migration, cell cycle control, chromatin remodeling, DNA damage response, and transcriptional regulation. MAPKAPK2 Protein, Human (His) is the recombinant human-derived MAPKAPK2 protein, expressed by E. coli , with N-6*His labeled tag and ΔH217-P237, S216G, , , mutation. The total length of MAPKAPK2 Protein, Human (His) is 318 a.a., .

HY-P701804

	MAPKAPK2 Protein, Human MAPKAPK2; MAP kinase-activated protein kinase 2; MAPK-activated protein kinase 2; MAPKAP kinase 2; MAPKAP-K2; MAPKAPK-2; MK-2; MK2	Human	E. coli
	The MAPKAPK2 protein is a stress-activated kinase involved in multiple cellular processes, including cytokine production, endocytosis, cytoskeletal reorganization, cell migration, cell cycle control, chromatin remodeling, DNA damage response, and transcriptional regulation. MAPKAPK2 Protein, Human is the recombinant human-derived MAPKAPK2 protein, expressed by E. coli , with tag free. and ΔH217-P237, S216G, , , mutation. The total length of MAPKAPK2 Protein, Human is 318 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.